ODP349 Risk of Coronavirus Disease 2019 (COVID-19) in patients with Cushing's Disease (CD) is increased and independently associated with both obesity and disease activity

Patients with Cushing's disease (CD) are usually immunosuppressed due to chronic hypercortisolism, therefore more susceptible to COVID-19. Comorbidities like obesity, hypertension and diabetes mellitus (DM), highly prevalent in CD, have been shown to increase severity of COVID-19 in the general...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the Endocrine Society 2022-11, Vol.6 (Supplement_1), p.A508-A509
Hauptverfasser: Mascarenhas Nakano, Bruna M, Fracacio, Silvia M, Brock, Paola W, Dias, Rossella F, Binda, Eduarda S, Miglioli, Adriana G, Santos-Neto, Pedro F, Portari, Luiz H, Sanudo, Adriana, Abucham, Julio
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page A509
container_issue Supplement_1
container_start_page A508
container_title Journal of the Endocrine Society
container_volume 6
creator Mascarenhas Nakano, Bruna M
Fracacio, Silvia M
Brock, Paola W
Dias, Rossella F
Binda, Eduarda S
Miglioli, Adriana G
Santos-Neto, Pedro F
Portari, Luiz H
Sanudo, Adriana
Abucham, Julio
description Patients with Cushing's disease (CD) are usually immunosuppressed due to chronic hypercortisolism, therefore more susceptible to COVID-19. Comorbidities like obesity, hypertension and diabetes mellitus (DM), highly prevalent in CD, have been shown to increase severity of COVID-19 in the general population. The aim of this study was to evaluate the incidence, risk factors, and outcome of COVID-19 in a cohort of CD patients from February/15 2020 to November/15 2021 (before the arrival of the Omicron variant in Brazil). Sixty out of 66 CD patients were included (54F). From October/1 to November/30/2021, patients or family members answered a questionnaire about the diagnosis and time of COVID-19 infection (PCR-confirmed), its outcome and vaccination status through phone interview. Clinical and biochemical data, obtained from our electronic medical records, showed that 15 patients were in hypercortisolism (25%) and 45 were in remission (75%). A similar proportion was found among those 6 patients that did not participate in the study. The cumulative incidence of COVID-19 in the cohort during the entire observation period (22 months) was 32% (19/60), much higher than reported in the general reference population within the same area during the same period (9.5%). Since vaccination only started in February/2021, 55 patients were considered as not fully vaccinated (less than two doses) up to July/2021 (observation period: 17 months). In those patients, the cumulative incidence of COVID-19 during that period of time was also higher (27%) than in the reference population (8.4%). When CD patients were stratified according to comorbidities, the cumulative incidence of COVID-19 was shown to be significantly higher in patients with active disease (hypercortisolism) [57%vs 17%,P= 0. 012] and in those with obesity [54%vs 9%,P
doi_str_mv 10.1210/jendso/bvac150.1058
format Article
fullrecord <record><control><sourceid>pubmedcentral_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9625641</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_9625641</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1448-fe2882b445291d475d0dd23995fbf3b1b449c92f11b627eff0b0d43b6a1824b63</originalsourceid><addsrcrecordid>eNpVUctKAzEUHUTBUvsFbrKzLmqTTOaRjSAzPgqFiqjbkEySNrWdDMl0pN_kT5o-8LFJ7j0vLpwoukTwBmEEx0tVS2_HouMVSgIGk_wk6mGS4RGiGT79M59HA--XEEJEY0IJ6UVfs_I5jODF-A9gNSisszXvjNt4UBqvuFcABzkYFrP3SRlSroGpQcNbo-rWg0_TLkCx8QtTz69-LcOiDDofpJXbARLwWoZNqiZcG5yrLeDe28rwNpD7FGHDY4Xypt3u5fIYxqvWdAG8iM40X3k1OP796O3h_rV4Gk1nj5PibjqqECH5SCuc51gQkmCKJMkSCaXEMaWJFjoWKDC0olgjJFKcKa2hgJLEIuUox0SkcT-6PeQ2G7FWsgrnOr5ijTNr7rbMcsP-M7VZsLntGE1xkhIUAuJDQOWs907pHy-CbNcZO3TGjp2xXWfxN7VTjrk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>ODP349 Risk of Coronavirus Disease 2019 (COVID-19) in patients with Cushing's Disease (CD) is increased and independently associated with both obesity and disease activity</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford Journals Open Access Collection</source><source>PubMed Central</source><creator>Mascarenhas Nakano, Bruna M ; Fracacio, Silvia M ; Brock, Paola W ; Dias, Rossella F ; Binda, Eduarda S ; Miglioli, Adriana G ; Santos-Neto, Pedro F ; Portari, Luiz H ; Sanudo, Adriana ; Abucham, Julio</creator><creatorcontrib>Mascarenhas Nakano, Bruna M ; Fracacio, Silvia M ; Brock, Paola W ; Dias, Rossella F ; Binda, Eduarda S ; Miglioli, Adriana G ; Santos-Neto, Pedro F ; Portari, Luiz H ; Sanudo, Adriana ; Abucham, Julio</creatorcontrib><description>Patients with Cushing's disease (CD) are usually immunosuppressed due to chronic hypercortisolism, therefore more susceptible to COVID-19. Comorbidities like obesity, hypertension and diabetes mellitus (DM), highly prevalent in CD, have been shown to increase severity of COVID-19 in the general population. The aim of this study was to evaluate the incidence, risk factors, and outcome of COVID-19 in a cohort of CD patients from February/15 2020 to November/15 2021 (before the arrival of the Omicron variant in Brazil). Sixty out of 66 CD patients were included (54F). From October/1 to November/30/2021, patients or family members answered a questionnaire about the diagnosis and time of COVID-19 infection (PCR-confirmed), its outcome and vaccination status through phone interview. Clinical and biochemical data, obtained from our electronic medical records, showed that 15 patients were in hypercortisolism (25%) and 45 were in remission (75%). A similar proportion was found among those 6 patients that did not participate in the study. The cumulative incidence of COVID-19 in the cohort during the entire observation period (22 months) was 32% (19/60), much higher than reported in the general reference population within the same area during the same period (9.5%). Since vaccination only started in February/2021, 55 patients were considered as not fully vaccinated (less than two doses) up to July/2021 (observation period: 17 months). In those patients, the cumulative incidence of COVID-19 during that period of time was also higher (27%) than in the reference population (8.4%). When CD patients were stratified according to comorbidities, the cumulative incidence of COVID-19 was shown to be significantly higher in patients with active disease (hypercortisolism) [57%vs 17%,P= 0. 012] and in those with obesity [54%vs 9%,P&lt;0. 001], but not with hypertension or DM. In multivariate analysis, both hypercortisolism and obesity were independent risk factors for COVID-19 in CD patients [RR=2.1 (CI: 1-4.4),P=0. 05 andRR=4.8 (CI: 1.5-15.5),P=0. 009, respectively]. One single patient (5.2%) died from COVID-19 (she had hypercortisolism, obesity, hypertension and DM). During the next 5 months, when all 60 patients had been fully vaccinated, there were four (4/41) new infections and no (0/19) reinfection. The incidence of COVID-19 is higher in CD patients and is associated with hypercortisolism, as expected, and more strongly with obesity, which is a novel and unexpected finding that has only recently been reported in the general population (1). Thus, correction of hypercortisolism, obesity, and preventive measures should be more aggressively implemented in CD patients during the current COVID-19 pandemia. Reference: (1) Recalde et al., J Clin Endocrinol Metab. 2021 Nov 19;106(2): e5030-e5042. Presentation: No date and time listed</description><identifier>ISSN: 2472-1972</identifier><identifier>EISSN: 2472-1972</identifier><identifier>DOI: 10.1210/jendso/bvac150.1058</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Neuroendocrinology and Pituitary</subject><ispartof>Journal of the Endocrine Society, 2022-11, Vol.6 (Supplement_1), p.A508-A509</ispartof><rights>The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625641/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625641/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Mascarenhas Nakano, Bruna M</creatorcontrib><creatorcontrib>Fracacio, Silvia M</creatorcontrib><creatorcontrib>Brock, Paola W</creatorcontrib><creatorcontrib>Dias, Rossella F</creatorcontrib><creatorcontrib>Binda, Eduarda S</creatorcontrib><creatorcontrib>Miglioli, Adriana G</creatorcontrib><creatorcontrib>Santos-Neto, Pedro F</creatorcontrib><creatorcontrib>Portari, Luiz H</creatorcontrib><creatorcontrib>Sanudo, Adriana</creatorcontrib><creatorcontrib>Abucham, Julio</creatorcontrib><title>ODP349 Risk of Coronavirus Disease 2019 (COVID-19) in patients with Cushing's Disease (CD) is increased and independently associated with both obesity and disease activity</title><title>Journal of the Endocrine Society</title><description>Patients with Cushing's disease (CD) are usually immunosuppressed due to chronic hypercortisolism, therefore more susceptible to COVID-19. Comorbidities like obesity, hypertension and diabetes mellitus (DM), highly prevalent in CD, have been shown to increase severity of COVID-19 in the general population. The aim of this study was to evaluate the incidence, risk factors, and outcome of COVID-19 in a cohort of CD patients from February/15 2020 to November/15 2021 (before the arrival of the Omicron variant in Brazil). Sixty out of 66 CD patients were included (54F). From October/1 to November/30/2021, patients or family members answered a questionnaire about the diagnosis and time of COVID-19 infection (PCR-confirmed), its outcome and vaccination status through phone interview. Clinical and biochemical data, obtained from our electronic medical records, showed that 15 patients were in hypercortisolism (25%) and 45 were in remission (75%). A similar proportion was found among those 6 patients that did not participate in the study. The cumulative incidence of COVID-19 in the cohort during the entire observation period (22 months) was 32% (19/60), much higher than reported in the general reference population within the same area during the same period (9.5%). Since vaccination only started in February/2021, 55 patients were considered as not fully vaccinated (less than two doses) up to July/2021 (observation period: 17 months). In those patients, the cumulative incidence of COVID-19 during that period of time was also higher (27%) than in the reference population (8.4%). When CD patients were stratified according to comorbidities, the cumulative incidence of COVID-19 was shown to be significantly higher in patients with active disease (hypercortisolism) [57%vs 17%,P= 0. 012] and in those with obesity [54%vs 9%,P&lt;0. 001], but not with hypertension or DM. In multivariate analysis, both hypercortisolism and obesity were independent risk factors for COVID-19 in CD patients [RR=2.1 (CI: 1-4.4),P=0. 05 andRR=4.8 (CI: 1.5-15.5),P=0. 009, respectively]. One single patient (5.2%) died from COVID-19 (she had hypercortisolism, obesity, hypertension and DM). During the next 5 months, when all 60 patients had been fully vaccinated, there were four (4/41) new infections and no (0/19) reinfection. The incidence of COVID-19 is higher in CD patients and is associated with hypercortisolism, as expected, and more strongly with obesity, which is a novel and unexpected finding that has only recently been reported in the general population (1). Thus, correction of hypercortisolism, obesity, and preventive measures should be more aggressively implemented in CD patients during the current COVID-19 pandemia. Reference: (1) Recalde et al., J Clin Endocrinol Metab. 2021 Nov 19;106(2): e5030-e5042. Presentation: No date and time listed</description><subject>Neuroendocrinology and Pituitary</subject><issn>2472-1972</issn><issn>2472-1972</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpVUctKAzEUHUTBUvsFbrKzLmqTTOaRjSAzPgqFiqjbkEySNrWdDMl0pN_kT5o-8LFJ7j0vLpwoukTwBmEEx0tVS2_HouMVSgIGk_wk6mGS4RGiGT79M59HA--XEEJEY0IJ6UVfs_I5jODF-A9gNSisszXvjNt4UBqvuFcABzkYFrP3SRlSroGpQcNbo-rWg0_TLkCx8QtTz69-LcOiDDofpJXbARLwWoZNqiZcG5yrLeDe28rwNpD7FGHDY4Xypt3u5fIYxqvWdAG8iM40X3k1OP796O3h_rV4Gk1nj5PibjqqECH5SCuc51gQkmCKJMkSCaXEMaWJFjoWKDC0olgjJFKcKa2hgJLEIuUox0SkcT-6PeQ2G7FWsgrnOr5ijTNr7rbMcsP-M7VZsLntGE1xkhIUAuJDQOWs907pHy-CbNcZO3TGjp2xXWfxN7VTjrk</recordid><startdate>20221101</startdate><enddate>20221101</enddate><creator>Mascarenhas Nakano, Bruna M</creator><creator>Fracacio, Silvia M</creator><creator>Brock, Paola W</creator><creator>Dias, Rossella F</creator><creator>Binda, Eduarda S</creator><creator>Miglioli, Adriana G</creator><creator>Santos-Neto, Pedro F</creator><creator>Portari, Luiz H</creator><creator>Sanudo, Adriana</creator><creator>Abucham, Julio</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20221101</creationdate><title>ODP349 Risk of Coronavirus Disease 2019 (COVID-19) in patients with Cushing's Disease (CD) is increased and independently associated with both obesity and disease activity</title><author>Mascarenhas Nakano, Bruna M ; Fracacio, Silvia M ; Brock, Paola W ; Dias, Rossella F ; Binda, Eduarda S ; Miglioli, Adriana G ; Santos-Neto, Pedro F ; Portari, Luiz H ; Sanudo, Adriana ; Abucham, Julio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1448-fe2882b445291d475d0dd23995fbf3b1b449c92f11b627eff0b0d43b6a1824b63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Neuroendocrinology and Pituitary</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mascarenhas Nakano, Bruna M</creatorcontrib><creatorcontrib>Fracacio, Silvia M</creatorcontrib><creatorcontrib>Brock, Paola W</creatorcontrib><creatorcontrib>Dias, Rossella F</creatorcontrib><creatorcontrib>Binda, Eduarda S</creatorcontrib><creatorcontrib>Miglioli, Adriana G</creatorcontrib><creatorcontrib>Santos-Neto, Pedro F</creatorcontrib><creatorcontrib>Portari, Luiz H</creatorcontrib><creatorcontrib>Sanudo, Adriana</creatorcontrib><creatorcontrib>Abucham, Julio</creatorcontrib><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of the Endocrine Society</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mascarenhas Nakano, Bruna M</au><au>Fracacio, Silvia M</au><au>Brock, Paola W</au><au>Dias, Rossella F</au><au>Binda, Eduarda S</au><au>Miglioli, Adriana G</au><au>Santos-Neto, Pedro F</au><au>Portari, Luiz H</au><au>Sanudo, Adriana</au><au>Abucham, Julio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ODP349 Risk of Coronavirus Disease 2019 (COVID-19) in patients with Cushing's Disease (CD) is increased and independently associated with both obesity and disease activity</atitle><jtitle>Journal of the Endocrine Society</jtitle><date>2022-11-01</date><risdate>2022</risdate><volume>6</volume><issue>Supplement_1</issue><spage>A508</spage><epage>A509</epage><pages>A508-A509</pages><issn>2472-1972</issn><eissn>2472-1972</eissn><abstract>Patients with Cushing's disease (CD) are usually immunosuppressed due to chronic hypercortisolism, therefore more susceptible to COVID-19. Comorbidities like obesity, hypertension and diabetes mellitus (DM), highly prevalent in CD, have been shown to increase severity of COVID-19 in the general population. The aim of this study was to evaluate the incidence, risk factors, and outcome of COVID-19 in a cohort of CD patients from February/15 2020 to November/15 2021 (before the arrival of the Omicron variant in Brazil). Sixty out of 66 CD patients were included (54F). From October/1 to November/30/2021, patients or family members answered a questionnaire about the diagnosis and time of COVID-19 infection (PCR-confirmed), its outcome and vaccination status through phone interview. Clinical and biochemical data, obtained from our electronic medical records, showed that 15 patients were in hypercortisolism (25%) and 45 were in remission (75%). A similar proportion was found among those 6 patients that did not participate in the study. The cumulative incidence of COVID-19 in the cohort during the entire observation period (22 months) was 32% (19/60), much higher than reported in the general reference population within the same area during the same period (9.5%). Since vaccination only started in February/2021, 55 patients were considered as not fully vaccinated (less than two doses) up to July/2021 (observation period: 17 months). In those patients, the cumulative incidence of COVID-19 during that period of time was also higher (27%) than in the reference population (8.4%). When CD patients were stratified according to comorbidities, the cumulative incidence of COVID-19 was shown to be significantly higher in patients with active disease (hypercortisolism) [57%vs 17%,P= 0. 012] and in those with obesity [54%vs 9%,P&lt;0. 001], but not with hypertension or DM. In multivariate analysis, both hypercortisolism and obesity were independent risk factors for COVID-19 in CD patients [RR=2.1 (CI: 1-4.4),P=0. 05 andRR=4.8 (CI: 1.5-15.5),P=0. 009, respectively]. One single patient (5.2%) died from COVID-19 (she had hypercortisolism, obesity, hypertension and DM). During the next 5 months, when all 60 patients had been fully vaccinated, there were four (4/41) new infections and no (0/19) reinfection. The incidence of COVID-19 is higher in CD patients and is associated with hypercortisolism, as expected, and more strongly with obesity, which is a novel and unexpected finding that has only recently been reported in the general population (1). Thus, correction of hypercortisolism, obesity, and preventive measures should be more aggressively implemented in CD patients during the current COVID-19 pandemia. Reference: (1) Recalde et al., J Clin Endocrinol Metab. 2021 Nov 19;106(2): e5030-e5042. Presentation: No date and time listed</abstract><cop>US</cop><pub>Oxford University Press</pub><doi>10.1210/jendso/bvac150.1058</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2472-1972
ispartof Journal of the Endocrine Society, 2022-11, Vol.6 (Supplement_1), p.A508-A509
issn 2472-1972
2472-1972
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9625641
source DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford Journals Open Access Collection; PubMed Central
subjects Neuroendocrinology and Pituitary
title ODP349 Risk of Coronavirus Disease 2019 (COVID-19) in patients with Cushing's Disease (CD) is increased and independently associated with both obesity and disease activity
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T07%3A28%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ODP349%20Risk%20of%20Coronavirus%20Disease%202019%20(COVID-19)%20in%20patients%20with%20Cushing's%20Disease%20(CD)%20is%20increased%20and%20independently%20associated%20with%20both%20obesity%20and%20disease%20activity&rft.jtitle=Journal%20of%20the%20Endocrine%20Society&rft.au=Mascarenhas%20Nakano,%20Bruna%20M&rft.date=2022-11-01&rft.volume=6&rft.issue=Supplement_1&rft.spage=A508&rft.epage=A509&rft.pages=A508-A509&rft.issn=2472-1972&rft.eissn=2472-1972&rft_id=info:doi/10.1210/jendso/bvac150.1058&rft_dat=%3Cpubmedcentral_cross%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_9625641%3C/pubmedcentral_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true